These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 17497486)

  • 1. Promotional methods used by representatives of drug companies: a prospective survey in general practice.
    Schramm J; Andersen M; Vach K; Kragstrup J; Kampmann JP; Søndergaard J
    Scand J Prim Health Care; 2007 Jun; 25(2):93-7. PubMed ID: 17497486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Drug marketing: methods, effect and regulation].
    Søndergaard J; Koefoed MM; Andersen M
    Ugeskr Laeger; 2009 Mar; 171(10):778-80. PubMed ID: 19265598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of pharmaceutical representative visits on GPs' drug preferences.
    Søndergaard J; Vach K; Kragstrup J; Andersen M
    Fam Pract; 2009 Jun; 26(3):204-9. PubMed ID: 19273463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of pharmaceutical promotion on prescribing decisions of general practitioners in Eastern Turkey.
    Vancelik S; Beyhun NE; Acemoglu H; Calikoglu O
    BMC Public Health; 2007 Jun; 7():122. PubMed ID: 17592644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determinants of the range of drugs prescribed in general practice: a cross-sectional analysis.
    de Bakker DH; Coffie DS; Heerdink ER; van Dijk L; Groenewegen PP
    BMC Health Serv Res; 2007 Aug; 7():132. PubMed ID: 17711593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Attitudes of general practitioners to pharmaceutical sales representatives in Sousse].
    Ben Abdelaziz A; Harrabi I; Rahmani S; Ghedira A; Gaha K; Ghannem H
    East Mediterr Health J; 2003; 9(5-6):1075-83. PubMed ID: 16450540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differences in prescribing between GPs: impact of the cooperation with pharmacists and impact of visits from pharmaceutical industry representatives.
    Muijrers PE; Grol RP; Sijbrandij J; Janknegt R; Knottnerus JA
    Fam Pract; 2005 Dec; 22(6):624-30. PubMed ID: 16055474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interactions with the pharmaceutical industry: experiences and attitudes of psychiatry residents, interns and clerks.
    Hodges B
    CMAJ; 1995 Sep; 153(5):553-9. PubMed ID: 7641153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Critical evaluation of the claims made by pharmaceutical companies in drug promotional material in Pakistan.
    Rohra DK; Gilani AH; Memon IK; Perven G; Khan MT; Zafar H; Kumar R
    J Pharm Pharm Sci; 2006; 9(1):50-9. PubMed ID: 16849008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paediatric homoeopathy in general practice: where, when and why?
    Ekins-Daukes S; Helms PJ; Taylor MW; Simpson CR; McLay JS
    Br J Clin Pharmacol; 2005 Jun; 59(6):743-9. PubMed ID: 15948942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmaceutical promotion and GP prescription behaviour.
    Windmeijer F; de Laat E; Douven R; Mot E
    Health Econ; 2006 Jan; 15(1):5-18. PubMed ID: 15945041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Written drug advertisements--are they reliable?].
    Solhaug HR; Indermo H; Slørdal L; Spigset O
    Tidsskr Nor Laegeforen; 2006 May; 126(10):1314-7. PubMed ID: 16691265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [GPs' perceptions of the Institute for Rational Pharmacotherapy].
    Gudex C; Hoffmann M; Brørs O; Dahlqvist R
    Ugeskr Laeger; 2009 Feb; 171(7):522-6. PubMed ID: 19210936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient awareness and concern regarding pharmaceutical manufacturer interactions with doctors.
    Edwards D; Ballantyne A
    Intern Med J; 2009 Mar; 39(3):191-6. PubMed ID: 19383067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A cross-sectional evidence-based review of pharmaceutical promotional marketing brochures and their underlying studies: is what they tell us important and true?
    Cardarelli R; Licciardone JC; Taylor LG
    BMC Fam Pract; 2006 Mar; 7():13. PubMed ID: 16515686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmaceutical industry influences on physician prescribing: gifts, quasi-gifts, and patient-directed gifts.
    Berger JT
    Am J Bioeth; 2003; 3(3):56-7. PubMed ID: 14594495
    [No Abstract]   [Full Text] [Related]  

  • 17. [Attitudes and behaviors of psychiatry residents and psychiatrists working in training institutes towards the relationship between the pharmaceutical industry and physicians].
    Gülöksüz S; Oral ET; Ulaş H
    Turk Psikiyatri Derg; 2009; 20(3):236-42. PubMed ID: 19757223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What information do physicians receive from pharmaceutical representatives?
    Lexchin J
    Can Fam Physician; 1997 May; 43():941-5. PubMed ID: 9154366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A national survey of the home visiting practice and attitudes of family physicians and internists.
    Keenan JM; Boling PE; Schwartzberg JG; Olson L; Schneiderman M; McCaffrey DJ; Ripsin CM
    Arch Intern Med; 1992 Oct; 152(10):2025-32. PubMed ID: 1417375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Attitudes of general practitioners to their interactions with pharmaceutical companies: a qualitative study.
    Quinn RJ; O'Neill C
    Ir Med J; 2002; 95(7):199-202. PubMed ID: 12227525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.